FORMA MX · Exo-meso fusion
MX-Clear
Clarity. Balance. Renewal.
Scroll
01 — 06
Science-backed formulation
Purify. Rebalance.
Niacinamideregulates sebum, reduces redness and inflammation
Azelaic derivativetargets acne-causing bacteria, calms the skin
Salicylic acidexfoliates inside pores, unclogs and prevents breakouts
Olive callus EVsplant-derived exosomes for repair and renewal
Clinical benefits & evidence
Proven on real skin.
Backed by science. Proven by results — measured over a 4-week clinical evaluation.
−38% sebum production
reduced excess oil and shine
reduced excess oil and shine
−42% pore size
visibly minimized pores
visibly minimized pores
+61% barrier function
stronger, more resilient skin
stronger, more resilient skin
+55% skin clarity
brighter, cleaner, more even complexion
brighter, cleaner, more even complexion
−33% redness & irritation
calmer skin with reduced visible redness
calmer skin with reduced visible redness
Indications
For oily and acne-prone skin.
Acne and inflammation · excess sebum · enlarged pores · post-acne texture — non-comedogenic, dermatologically tested.
The protocol
Simple. Repeatable.
Superficial mesotherapy by qualified practitioners.
2–3 ml per session
distributed across the treatment area
distributed across the treatment area
4 sessions
recommended initial course
recommended initial course
Every 2–3 weeks
session frequency
session frequency
FORMA MX-Clear
Ready when you are.
- Format
- 3 × 10 ml vials
- Technology
- Exo-meso fusion
- Key actives
- Niacinamide · azelaic derivative · salicylic acid
- Skin
- Oily · acne-prone
- Frequency
- Every 2–3 weeks
- Use
- Professional only
Full composition (INCI)
Aqua, Disodium phosphate, Glycerin, Niacinamide, Benzyl alcohol, Phenoxyethanol, Panthenol, Azelamidopropyl dimethyl amine, Salicylic acid, Alanine, Allantoin, Histidine HCl, Sodium hyaluronate, Sodium phosphate, 1,3-Butylene glycol, Dextrin, Polydextrose, Olea europaea (olive) callus extracellular vesicles, Amylopectin.
As declared. For professional use only — review before use in patients with known sensitivities.
